心肾综合征的新认识

The new recognition of cardiorenal syndrome

心脏和肾脏在心、肾疾病的发生发展中是两个互为影响的重要器官。研究发现,肺也参与心肾疾病的病理生理过程,从而使传统意义的心肾综合征(CRS)定义面临新的挑战。CRS临床表现多样,发病机制复杂,显著增加治疗的复杂性和患者的死亡风险,特异性生物活性指标如肿瘤性抑癌基因2(ST2)、成纤维细胞生长因子23(FGF23)等的检测可于病程早期对此类疾病予以有效干预。因此,有必要从临床特点、病理生理机制、生物活性检测指标及治疗等方面进一步提高对CRS的全新认识以有效指导临床。

Heart and kidney affected mutually,are two important organs,which take part in the occurrence and development process of heart and kidney diseases.In the current study,researchers have demonstrated the involvement of lungs which play a striking role in the physiopathologic process of heart and kidney diseases,thus the traditional definition of cardiorenal syndrome（CRS） is faced with new challenges.CRS not only has diversity clinical manifestations,but also owns complicated pathogenesises,which give rise to a more mazy therapy and to the increase of mortality risk.These diseases may be interposed effectively by detecting specific biological markers such as suppressor of tumorigenicity 2,fibroblast growth factor 23 and so on at early stages.Therefore,it is necessary to improve the comprehensive cognition of CRS from clinical characteristics,pathophysiologic mechanism,biomarker detection,and therapy,so as to receive effective guidance in clinic.